You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動 | 澤璟製藥-U漲10% 鹽酸傑克替尼片新藥上市申請獲受理
格隆匯 10-17 10:14
格隆匯10月17日丨澤璟製藥-U(688266.SH)漲10.39%,報40.25元,總市值97億元。澤璟製藥16日公吿,公司收到國家藥品監督管理局核准簽發的《受理通知書》,公司遞交的鹽酸傑克替尼片新藥上市申請(NDA)獲得受理。本次獲得受理的新藥上市申請的適應症是用於治療中、高危骨髓纖維化,這是鹽酸傑克替尼片首個申請新藥上市的適應症。根據公開資料查詢,鹽酸傑克替尼片是第一個申請新藥上市的國產JAK抑制劑類創新藥物。鹽酸傑克替尼片治療中、高危骨髓纖維化的III期臨牀試驗期中分析結果達到了方案預設的主要療效終點。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account